...
首页> 外文期刊>Biological & pharmaceutical bulletin >Comparative study on pharmacokinetics and in vivo alpha1-adrenoceptor binding of [3H]tamsulosin and [3H]prazosin in rats.
【24h】

Comparative study on pharmacokinetics and in vivo alpha1-adrenoceptor binding of [3H]tamsulosin and [3H]prazosin in rats.

机译:[3H]坦索罗辛和[3H]吡唑嗪在大鼠体内的药代动力学和体内α1-肾上腺素受体结合的比较研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The plasma concentration, total radioactivity and in vivo alpha1-adrenoceptor binding in rat tissues after intravenous (i.v.) injection of [3H]tamsulosin were measured and they were compared with those obtained after the injection of [3H]prazosin. The plasma concentration of [3H]tamsulosin was consistently higher than that of [3H]prazosin, with 1.4 times greater areas under the curve (AUC(0-infinity)) of plasma concentration. As there was a significantly lower value of apparent volume of central compartment (Vd(c)) and distribution volume at steady state (Vd(ss)) for [3H]tamsulosin than [3H]prazosin with little difference in elimination rate constant (beta), the higher concentration of [3H]tamsulosin in plasma might be associated mainly with the smaller volume of distribution. The ratio of total radioactivity in tissues to the plasma unbound concentration of [3H]tamsulosin after i.v. injection of the ligand was consistently lower than that of [3H]prazosin. These observations suggest that [3H]tamsulosin is distributed in rat tissues in a more limited manner than [3H]prazosin. A significantly lower level of in vivo specific binding of [3H]tamsulosin than [3H]prazosin was observed in the spleen, heart and liver. Further, the apparent dissociation constant (Kd) and maximal number of binding sites (Bmax) for in vivo specific [3H]tamsulosin binding were considerably lower than those for [3H]prazosin binding. Therefore, these findings suggest that [3H]tamsulosin labels preferentially a subpopulation of the alpha1-adrenoceptor sites in rat tissues labeled by [3H]prazosin. In conclusion, the present study has shown that there is a significant difference in the pharmacokinetics and in vivo alpha1-adrenoceptor binding characteristics between tamsulosin and prazosin.
机译:在静脉内(i.v.)注射[3H]坦索罗辛后,测量大鼠组织中的血浆浓度,总放射活性和体内α1-肾上腺素受体结合,并将其与注射[3H]普唑嗪后获得的血浆中浓度,总放射性和体内α1-肾上腺素受体结合。 [3H]坦索罗辛的血浆浓度始终高于[3H]吡唑嗪的血浆浓度,血浆浓度曲线下的面积(AUC(0-无穷大))下比区域大1.4倍。由于[3H]坦索罗辛的中央室表观体积(Vd(c))和稳态下的分布体积(Vd(ss))的值明显低于[3H]哌唑嗪,消除速率常数(β ),血浆中[3H]坦洛新的浓度较高可能主要与较小的分布量有关。静脉注射后组织中总放射性与[3H]坦索罗辛血浆未结合浓度的比率。配体的注射始终低于[3H]哌唑嗪。这些观察结果表明,[3H]坦索罗辛比[3H]吡唑嗪在大鼠组织中的分布更为有限。在脾脏,心脏和肝脏中观察到[3H]坦索罗辛的体内特异性结合水平明显低于[3H]吡唑嗪的体内特异性结合水平。此外,体内特异性[3H]坦索罗辛结合的表观解离常数(Kd)和最大结合位点(Bmax)明显低于[3H]普拉唑嗪结合的表观解离常数(Kd)和最大结合位点数(Bmax)。因此,这些发现表明,[3H]坦索罗辛标记物优先在大鼠组织中被[3H]吡唑嗪标记的α1-肾上腺素受体位点的亚群。总之,本研究表明坦索罗辛和哌唑嗪之间的药代动力学和体内α1-肾上腺素受体结合特征存在显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号